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Abstract 
Epigenetics finely tunes gene expression at a functional 
level without modifying the DNA sequence, thereby 
contributing to the complexity of genomic regulation. 
Satellite cells (SCs) are adult muscle stem cells that 
are important for skeletal post-natal muscle growth, 
homeostasis and repair. The understanding of the 
epigenome of SCs at different stages and of the 
multiple layers of the post-transcriptional regulation 
of gene expression is constantly expanding. Dynamic 
interactions between different epigenetic mechanisms 
regulate the appropriate timing of muscle-specific gene 
expression and influence the lineage fate of SCs. In 
this review, we report and discuss the recent literature 
about the epigenetic control of SCs during the myogenic 
process from activation to proliferation and from their 
commitment to a muscle cell fate to their differentiation 
and fusion to myotubes. We describe how the co-
ordinated activities of the histone methyltransferase 
families Polycomb group (PcG), which represses the 
expression of developmentally regulated genes, and 
Trithorax group, which antagonizes the repressive activity 
of the PcG, regulate myogenesis by restricting gene 
expression in a time-dependent manner during each 
step of the process. We discuss how histone acetylation 
and deacetylation occurs in specific loci throughout 
SC differentiation to enable the time-dependent trans-
cription of specific genes. Moreover, we describe the 
multiple roles of microRNA, an additional epigenetic 
mechanism, in regulating gene expression in SCs, by 
repressing or enhancing gene transcription or translation 
during each step of myogenesis. The importance of 
these epigenetic pathways in modulating SC activation 
and differentiation renders them as promising targets 
for disease interventions. Understanding the most 
recent findings regarding the epigenetic mechanisms 
that regulate SC behavior is useful from the perspective 
of pharmacological manipulation for improving muscle 
regeneration and for promoting muscle homeostasis 
under pathological conditions.
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Core tip: Skeletal muscle needs to efficiently respond to 
internal and external stimuli, and satellite cells (SCs), the 
stem cells of muscle, play key roles in the preservation of 
muscle mass under both physiological and pathological 
conditions. Epigenetic pathways participate in co-
ordinating the precise time-dependent expression of 
different subsets of myogenic genes in SCs. Thus, these 
pathways represent promising targets for therapeutic 
interventions. In this review, we focus on the epigenetic 
changes mediated by histone modifications - methylation 
or acetylation - and by noncoding mRNAs throughout SC 
differentiation.
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SATELLITE CELLS
The first report and ultrastructural description of satellite 
cells (SCs) was in 1961 when Mauro reported the 
presence of cells containing a scant cytoplasm that were 
“intimately associated with the muscle fiber wedged 
between the plasma membrane of the muscle fiber 
and the basement membrane”; Mauro termed them 
SCs[1]. In the same report, despite the absence of direct 
functional evidence, Mauro proposed that SCs “might 
be pertinent to the vexing problem of skeletal muscle 
regeneration”.
In subsequent decades, Mauro’s hypothesis proved 
true, and a number of studies demonstrated that SCs 
are the key mediators of post-natal skeletal muscle 
growth, homeostasis and repair[2-4]. The core functions 
of SCs are the repair of damaged muscle fibers and the 
maintenance of an adequate pool of stem cells. In fact, 
dividing SCs were shown by autoradiographic studies to 
supply both new nuclei within growing or regenerating 
muscle fibers and new SCs adjacent to the muscle 
fibers[5,6].
Quiescent SCs express the transcription factor Pax7[7]. 
However, quiescent SCs constitute a heterogeneous 
population: most SCs are committed to the myogenic 
lineage (Pax7+, Myf5+), whereas a small subpopulation 
of SCs (Pax7+, Myf5-) are interpreted as representing 
satellite stem cells, whose asymmetric division produces 
both Pax7+, Myf5- stem cells and Pax7+, Myf5+ committed 
SCs. SCs are also capable of maintaining or expanding 
their number via symmetric division[8,9]. The observation 
that SC proliferation contributes to both the growth or 
repair of the muscle fiber and the maintenance of the SC 
pool provided the basis for considering SCs as muscle 
stem cells[10]. The equilibrium between asymmetric 
and symmetric division is therefore relevant to the 
maintenance of a homeostatic population of stem cells. 
In SCs, this equilibrium is influenced by signaling that 
includes WNT7A and its receptor Frizzled 7 (Fzd7) via the 
-catenin-independent, non-canonical planar cell polarity 
pathway[11]. Such signals dictate the polarity (parallel or 
perpendicular) of the orientation of mitotic division with 
respect to the fiber sarcolemma (and the basal lamina). 
WNT7A activity induces stem cells to divide in a planar 
orientation, parallel to the fiber sarcolemma, thereby 
favoring symmetric division, which produces two Pax7+, 
Myf5- stem cells. Conversely, in the absence of WNT7A 
activity, the mitotic spindle is oriented perpendicular 
to the fiber sarcolemma, thereby favoring asymmetric 
division into two daughter cells; the daughter cell that 
contacts the basal lamina retains stem cell characteristics 
(Pax7+, Myf5-), whereas the other daughter cells, which 
contacts the fiber sarcolemma, becomes a Pax7+, Myf5+ 
committed SC.
SCs in muscle regeneration
Many stimuli, such as those present in injured or 
diseased muscle, induce SCs to activate, expand and 
contribute to new fiber formation. Importantly, SC 
activation is not restricted to the damaged area; rather, 
SC proliferation and migration to the regeneration 
site have been observed along entire fibers of injured 
muscles[12]. Muscle regeneration is absolutely dependent 
upon muscle-resident Pax7+ cells[13], which predominantly, 
although not exclusively, consist of SCs[14]. The absolute 
requirement of Pax7+ SCs for muscle regeneration 
was demonstrated in different studies[13,15,16]. In the 
absence of Pax7+ SCs, regeneration does not take 
place; instead, fibro-adipogenic cells invade the tissue. 
In keeping with the notion that SC-dependent muscle 
regeneration processes are similar to those of embryonic 
myogenesis, SC activation involves the upregulation 
of myogenic basic helix-loop-helix transcription factors 
and SC differentiation[17]. In particular, at the molecular 
level, the activation of SCs is characterized by the rapid 
expression of MyoD and Myf5, which is triggered by Pax7 
(and its paralog Pax3)[18] and is modulated by epigenetic 
mechanisms[19]. 
After the proliferation phase, the expression of 
the myogenesis regulatory factor (MRF) members 
myogenin and MRF4 is upregulated, leading to terminal 
SC differentiation[20]. This event is concomitant with 
the activation of the cell cycle arrest protein p21 and 
permanent exit from the cell cycle. The completion of 
the SC differentiation program includes the activation of 
muscle-specific proteins, such as myosin heavy chains, 
and the fusion of SCs to each other or the repair of 
damaged muscle. SC fusion, which is a complex and 
tightly controlled process[21], is regulated by numerous 
proteins involved in cell-cell adhesion and actin dy-
namics[22-25], as well as muscle-specific membrane 
proteins[26].
The depletion of SCs is a common occurrence in 
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chronic muscle degenerative diseases, and these cells 
cannot be replaced. Thus, the regulation of SC renewal 
is central to the promotion of muscle regeneration in 
muscle diseases, such as muscular dystrophies.
EPIGENETIC MECHANISMS OF GENE 
REGULATION
Epigenetics is responsible for the identity of distinct 
cell types despite the same genetic information by 
modulating gene expression without altering the genetic 
code. In other words, the ensemble of epigenetic 
characteristics, referred to as the epigenome, determines 
the gene expression pattern that defines the distinct 
characteristics and functions of each cell type[27]. In fact, 
although their genomes are essentially identical, the 
cell types in a multicellular organism perform strikingly 
different behaviors over extended periods. Lineage 
commitment during development is the most extreme 
example of epigenetics. During embryogenesis, cells 
progress from totipotency to terminal differentiation, and 
each step of this progression involves the establishment 
of a stable state in which specific developmental 
commitments that can be transmitted to daughter cells 
are encoded. The understanding of the epigenome 
of different cell types and the complexity of the post-
transcriptional control of gene expression is constantly 
expanding due to the development of new technologies 
and the continuous discovery of noncoding RNAs that 
participate in epigenetic regulation. 
Histone methylation
The eukaryotic genome is packaged into chromatin, a 
chain of nucleosomes composed of four core histones 
- H2A, H2B, H3, and H4 - whose amino-terminal 
tails are exposed on the surface of nucleosomes and 
are subjected to a wide range of post-translational 
modifications[28,29]. Gene activation and repression, as 
well as transcriptional initiation and elongation, are 
regulated by many such histone modifications. In the 
last decade, studies of human and mouse embryonic 
stem cells have delineated the role of the histone methyl-
transferase (HMT) families Polycomb group (PcG) and 
Trithorax group (TrxG) in modulating the pluripotency 
and lineage restriction of several cell types[30]. For 
instance, numerous trimethylations of histone 3 lysine 
4 (H3K4me3) mediated by the TrxG family surrounding 
the transcription start sites indicate transcriptional 
gene activation, and trimethylations of histone 3 
lysine 36 (H3K36me3) in the gene body are generally 
associated with active gene transcription; alternatively, 
the trimethylation of histone 3 lysine 27 (H3K27me3) 
mediated by the PcG complex is associated with 
transcriptional repression[28]. Although the repressive 
H3K27me3 mark is transmitted to daughter cells[31] and 
is dominant over the permissive H3K4me3 mark[32], 
transcriptional gene activation requires the demethylation 
of H3K27me3, which is mediated by the demethylase 
families lysine-specific demethylase 6A (Kdm6a) and 
KDM1 lysine-specific demethylase 6B (Kdm6b)[33-35]. 
Thus, whereas polycomb repressive complex 2 (PRC2) 
establishes gene silencing at developmentally regulated 
loci, the TrxG and Kdm6a/Kdm6b families work together 
to antagonize the repressive activity of PRC2 and to 
promote gene expression in specific cell types.
Histone acetylation
Histone acetylation modulates transcription via multiple 
mechanisms. The acetylation of lysine residues within 
histone tails neutralizes their positive charge, thereby 
facilitating chromatin relaxation and increasing the 
accessibility of transcription factors to their target 
genes[36]. Acetylated histones are also recognized as 
binding sites for transcriptional activators. Conversely, 
histone deacetylation induces transcriptional repression 
by compacting the chromatin structure[37]. The combined 
activities of two enzyme families, histone acetyltrans-
ferases (HATs) and deacetylases (HDACs), determine the 
overall levels of histone acetylation in the genome. Both 
HATs and HDACs act on chromatin by associating with a 
variety of DNA-binding transactivator proteins. In some 
cases, DNA targeting involves other chromatin-modifying 
activities, such as histone methylation. Thus, the effects 
of HATs and HDACs on gene regulation depend on the 
cell type and the spectrum of available partners[38].
Noncoding RNAs
Advances in the field of gene regulation mediated 
by single-stranded noncoding RNA molecules have 
demonstrated their importance in gene regulatory 
networks. Until recently, small noncoding RNAs (miRNAs) 
were believed to solely negatively regulate target 
mRNAs[39]. However, published studies are increasingly 
indicating that miRNAs can also stimulate gene ex-
pression in response to specific cellular conditions or 
cofactors[40]. miRNAs are able to reduce gene expression 
via multiple mechanisms. At the transcriptional level, 
miRNAs repress gene expression by pairing nucleotides 
2 to 8, termed the seed region, to the seed match site 
in the target mRNA, typically positioned at the 3’ UTR 
or, less frequently, at the 5’ UTR or the coding region[41]. 
In addition to transcriptional effects, miRNAs can 
repress translation initiation via multiple mechanisms, 
such as promoting mRNA degradation or interfering 
with the formation of closed-loop mRNA or other 
translation initiation factors[41]. Moreover, increasing 
evidence indicates that some miRNAs can upregulate 
gene expression in specific cell types and under certain 
conditions via the direct action of miRNAs or via the 
indirect inhibition of repressive miRNA activity[42]. Another 
class of noncoding RNAs, long noncoding RNAs, has 
been shown to take part in many transcription regulatory 
processes[43] and post-transcriptional events, such as 
mRNA stability and translational control[44-46], and to 
function as competing endogenous RNA[47-49] by acting 
as an miRNA sponge to participate with coding RNA in 
a regulatory circuit that controls the binding of RNA to 
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factors such as MyoD, SRF and Myf5[60], whose encoded 
proteins are the primary activators of the myogenic 
program. Consistent with the notion that H3K4me3 
alone does not predict the transcriptional state of a 
gene but rather marks the gene for transcriptional 
activation[61], neither the number nor the identity of 
genes marked by H3K4me3 is significantly different 
between activated and quiescent SCs. Indeed, SC 
activation is accompanied by the retention of H3K4me3 
and the acquisition of H3K27me3 via PcG members[62], 
often in association with the transcriptional repressors 
YY1 and HDAC1. Interestingly, low levels of H3K27me3 
are associated with the pluripotency of embryonic 
stem cells[56,63]. The current understanding is that the 
general lack of repressive H3K27me3 marks and the 
concomitant presence of H3K4me3 at the transcription 
start sites of a large number of genes may establish a 
permissive chromatin state that underlies and permits 
the pluripotency of stem cells. In addition, numerous 
transcription start sites across the genome of quiescent 
SCs contain bivalent chromatin domains[59], which are 
characterized by the concomitant presence of both 
H3K4me3 and H3K27me3 marks. Consistent with 
the presence of H3K27me3 marks, these genes are 
either not transcribed or transcribed at very low levels. 
Interestingly, bivalent domains correspond to genes 
that are associated with the development of other 
organs and tissues aside from muscle, suggesting 
that SCs retain the potential to adopt a non-myogenic 
fate because of the presence of bivalent domains that 
contribute to the determination of cell lineage[59].
miRNAs also contribute to the generation of an 
epigenetic state that enables the maintenance of the 
myogenic lineage in quiescent SCs and that facilitates the 
activation of muscle gene expression and the formation 
of differentiated myotubes in response to SC activation. 
An important role in the maintenance of muscle stem-cell 
quiescence has been demonstrated for microRNA-489, 
which is highly expressed in quiescent SCs, in which it 
suppresses the expression of the oncogene DEK, and 
which is rapidly downregulated upon SC differentiation[57]. 
Additionally, miR-31 has been demonstrated to play an 
important role in quiescent SCs[58]. In quiescent SCs, the 
Myf5 gene has already been transcribed but cannot be 
expressed because miR-31 functionally inactivates Myf5 
mRNA by retaining it inside cytoplasmic mRNP granules, 
thereby preventing its translation and blocking myogenic 
differentiation[58].
Epigenetic control of SC activation 
In response to different stimuli, e.g., muscle damage, 
SCs become activated, begin to express cell cycle 
markers, which are readily marked by the permissive 
H3K4me3[64], and re-enter the cell cycle. SCs that divide 
in a parallel orientation to the myofibers, undergo a 
symmetrical cell division and give rise to two SCs that 
can return to the quiescent state[8]. In contrast, cells that 
divide in the sagittal orientation undergo asymmetric 
cell division to produce one cell that returns to the 
miRNA. 
Reciprocal and dynamic interactions between 
different epigenetic mechanisms and transcription 
factors modulate gene expression. For instance, changes 
in histone modifications are caused by the recruitment 
of chromatin-modifying enzymes, such as HATs or HMTs, 
by transcription factors and the RNA polymerase Ⅱ 
complex[28]; at the same time, combinations of histone 
modifications in the proximity of consensus sequences 
may anticipate and direct the binding of the transcription 
factor, facilitating the transcriptional activation of a given 
gene[50]. 
Numerous epigenetic mechanisms regulate the 
different phases of myogenesis, including chromatin 
remodeling and post-transcriptional gene regulation 
mediated by noncoding RNAs[51-53]. Such orchestrated 
regulation permits the correct timing of muscle-specific 
gene expression and influences the fate of muscle 
progenitors into muscle or non-muscle cell lineages[54,55]. 
In this review, we report and discuss the recent literature 
about the epigenetic regulation of the myogenic process 
from activation to proliferation and SC commitment. 
We focus on the epigenetic changes, specifically those 
mediated by chromatin methylation or acetylation and 
noncoding RNA function to regulate gene expression, 
that occur during the different steps of SC differentiation. 
EPIGENETICS IN SCs
Epigenetics mediates most of the signaling integrating 
the regeneration cues released by interstitial cells 
and by the external environment within the SC niche. 
Our understanding of the highly coordinated layers of 
epigenetic regulation of SC maintenance, activation and 
differentiation and cross-talk of epigenetic regulatory 
mechanisms with muscle-specific transcriptional ma-
chinery has tremendously increased due to the recent 
results obtained via next-generation genome-wide 
sequencing[56]. Using ChIP-Seq experiments, chipped 
chromatin can currently be entirely mapped across the 
genome to identify the regions that are over-represented 
among these sequences, revealing the interactions 
between chromatin-remodeling enzymes, transcription 
factors and DNA, thereby facilitating the production of 
chromatin-state maps.
Epigenetic control of SC quiescence 
In quiescent SCs, while the Pax7 gene must be 
expressed, modulators of cell cycle progression and 
transcription factors of the myogenic lineage need to 
remain silenced. Increasing studies have suggested that 
quiescent SCs are not in a dormant state but rather are 
primed for activation and differentiation in response 
to external stimuli[57,58]. At the chromatin level, this 
primed state is maintained by the general lack of the 
repressive mark H3K27me3 across the genome and the 
concomitant presence of H3K4me3 at the transcription 
start sites of a large number of genes (nearly 50% of 
all annotated genes)[59], including myogenic regulatory 
Moresi V et al . Satellite cells: Beyond genes
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quiescent state and one proliferating myoblast[8]. The 
latter cell expresses the Myf5 and MyoD genes, as 
well as genes that regulate cell cycle progression, all 
of which are characterized by the enrichment of the 
transcriptionally permissive H3K4me3 mark within their 
associated chromatin[19]; Pax7 is progressively silenced 
while transitioning from a transcriptionally permissive 
state of H3K4me3 to a repressive state of H3K27me3 
throughout cell differentiation[65]. Additional mechanisms 
that regulate SC proliferation include p38-gamma MAPK, 
which phosphorylates the MyoD protein to reinforce the 
interaction between MyoD and the HMT KMT1A, and the 
consequent inhibition of the premature expression of 
the myogenin gene. Consistently, in p38-gamma MAPK-
null SCs, KMT1A cannot associate with the myogenin 
promoter; therefore, myogenin is expressed earlier, 
resulting in decreased SC proliferation and defective 
differentiation[66].
During myoblast proliferation, distinct classes of 
HDACs are also involved in the repression of muscle 
gene transcription by countering the activities of HATs. 
Whereas local hyper-acetylation at consensus MyoD-
binding sites in myoblasts likely predetermines the 
regions of chromatin accessibility, class Ⅰ and Ⅱ HDACs 
contribute to the hypo-acetylation of the MyoD gene 
and the inhibition of MEF2 transcription and activation, 
respectively. In undifferentiated SCs, MyoD interacts 
with HDAC1, and this interaction is responsible for 
silencing the MyoD-dependent transcription of p21 and 
muscle-specific genes[67,68]. Moreover, class Ⅱ HDACs 
are localized to the nucleus during SC proliferation and 
are responsible for blocking the activity of the myogenic 
co-factor MEF2[69]. A recent study of HDAC4 function 
and SC proliferation reported that the HDAC4 levels 
positively correlate with the expression of Pax7 and 
Lix1, both of which are important for appropriate SC 
proliferation[70]; however, the molecular mechanism 
underlying this phenomenon remains unclear.
SC proliferation is also promoted and maintained by 
miR-27a/b, which targets and downregulates myostatin 
mRNA[71]. Consistently, SCs treated with antagomirs 
specific to miR-27a/b displayed increased myostatin 
expression and reduced proliferation. In activated SCs, 
miR-27b plays an important role in determining the 
appropriate timing of myogenic gene expression and 
regulates the Pax3 protein levels to control the entry of 
these cells into the myogenic differentiation program[72]. 
SC proliferation is also promoted by miR-133a, which 
represses the expression of serum response factor[73], 
and by miR-682, which is highly upregulated during 
myoblast proliferation both in vitro and in vivo; the 
inhibition of miR-682 results in reduced myoblast 
proliferation[74]. Moreover, in activated SCs, tissue 
inhibitor of metalloproteinase 3 (TIMP3), an inhibitor of 
tumor necrosis factor (TNF)-alpha-converting enzyme, 
regulates TNF-alpha release and acts as a switch for 
myogenic differentiation. miR-206 promotes TIMP3 
downregulation[75] and suppresses Pax3 expression[74], 
thereby promoting SC differentiation. Paradoxically, 
quiescent SCs express high levels of both Pax3 and 
miR-206. An additional layer of gene regulation explains 
these contradictory data. In fact, it has been shown 
that in quiescent SCs, Pax3 transcripts are alternatively 
polyadenylated and are expressed as shorter 3’ UTR 
transcripts, thereby resulting in the resistance of Pax3 
expression to miR-206-mediated regulation[76].
Epigenetic control of SC differentiation 
As a general rule, genes no longer required for lineage 
progression are targeted for stable repression[59,62]. 
Accordingly, during differentiation, SC chromatin converts
to a more repressed state by accumulating H3K27me3 
across the genome at both transcription start sites and 
intergenic regions. In fact, in contrast to the level of 
H3K4me3, the level of the repressive mark H3K27me3 
is low in quiescent SCs and is dramatically increased in 
differentiating SCs. In particular, when SCs differentiate, 
PRC2 is released from muscle differentiation genes 
(MyoD and SRF) to translocate to loci that are typically 
repressed in differentiated myotubes, e.g., Pax7. By 
inducing a transition from the transcriptionally permissive 
mark H3K4me3 to the repressive mark H3K27me3 on 
the Pax7 gene, PRC2 contributes to the switching off of 
SC proliferation[65]. Similarly, a switch from the permissive 
mark H3K4me3 to the repressive mark H3K27me3 on 
genes involved in the cell cycle is mediated by the E2F 
family of transcription factors and by the retinoblastoma 
protein as the SC exits the cell cycle to terminally 
differentiate[64,77,78]. Moreover, Pax7 associates with 
the Wdr5-Ash2L-MLL2 HMT complex, which mediates 
H3K4me3[19]. The binding of the Pax7-HMT complex 
to Myf5 results in the formation of H3K4me3 on the 
surrounding chromatin. Thus, Pax7 also participates in 
the induction of chromatin modifications that stimulate 
transcriptional activation of target genes to regulate 
the entry into the myogenic developmental program. 
Concomitantly, lysine-specific demethylase 4A, together 
with heterochromatin protein 1 alpha, promotes the 
demethylation of H3K9me3 at myogenic promoters, 
facilitating myoblast commitment[79].
The Ezh2 subunit of PCR2 complex has been 
demonstrated to play a critical role in mediating SC 
differentiation into the skeletal muscle lineage by 
suppressing a subset of regulators of non-muscle cell 
fate. Indeed, Ezh2-mediated H3K27me3 marks are 
specifically present on genes associated with alternative 
lineage selection, although Ezh2 dos not suppress 
terminal differentiation into skeletal muscle[80]. In 
contrast to PRC2-Ezh2, PRC2-Ezh1 is required for the 
myogenic differentiation of SCs; specifically, PRC2-
Ezh1 replaces PRC2-Ezh2 on the myogenin promoter 
to regulate the appropriate timing of the transcriptional 
activation of myogenin[81].
When SCs differentiate, HDAC1 downregulation 
and pRb hypo-phosphorylation occurs, enabling the 
formation of the pRb-HDAC1 complex in differentiated 
myotubes. The pRb-HDAC1 interaction coincides 
with the disruption of the MyoD-HDAC1 complex, the 
Moresi V et al . Satellite cells: Beyond genes
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transcriptional activation of muscle-specific genes, and 
the differentiation of myoblasts[68]. Muscle differentiation 
also induces the nuclear-to-cytoplasmic translocation 
of class Ⅱ HDACs, thereby releasing the inhibitory 
constraints on MEF2 and consequently activating the 
expression of muscle-specific genes[69].
Over the course of differentiation, p38 alpha/beta 
MAPK activity increases and is required for complete 
myoblast differentiation and fusion, which is partially 
due to its regulation of the epigenetic mechanisms 
controlling gene expression[82]. In particular, p38alpha/
beta MAPK, by selectively enabling the recruitment 
of SWI-SNF to the gene promoters of myogenin and 
creatine kinase, facilitates chromatin remodeling and 
the consequent expression of muscle genes. Indeed, 
p38-alpha-null SCs display increased Pax7 expression, 
persistent proliferation, and impaired differentiation 
and fusion[83], highlighting the distinct role of different 
members of the p38 MAPK family in SC proliferation 
and differentiation. It appears likely that the relative 
abundance of p38-alpha and p38-gamma MAPK activity 
in activated SCs serves as a balance between SC 
proliferation and differentiation. 
As SCs differentiate, the downregulation of the 
enzymatic subunit of PRC2-Ezh2 and its partner YY1 is 
mediated by the combined action of miR-214[84], miR-
26a[85] and miR-29[86], thereby relieving PRC2-mediated 
repression of muscle genes. Once SCs differentiate, 
miR-128a, miR-1 and miR-206 cooperate to block cell 
proliferation by inhibiting the expression of several 
targets in the insulin signaling pathway and Pax7 
expression[87,88]. Indeed, the loss of miR-1 and miR-206 
increases Pax7 expression, enhances SC proliferation 
and significantly inhibits myoblast differentiation[87,89]. 
The inhibition of cell proliferation is also achieved via the 
downregulation of the Ccnd1 gene by both miR-26a and 
miR-1[90]. In addition, miR-133a and miR-133b inhibit 
cell proliferation and promote myoblast differentiation 
by negatively regulating the FGFR1 and PP2AC pro-
teins, which participate in ERK1/2-mediated signal 
transduction[91]. In addition to inhibiting Pax7, miR-206 
promotes SC differentiation and fusion to muscle fibers 
via the suppression of a collection of negative regulators 
of myogenesis, such as notch3, igfbp5, Meox2, RARB, 
Fzd7, MAP4K3, CLCN3, and NFAT5[89,92]. An important 
role in determining SC lineage commitment has been 
attributed to miR-133[93]. By targeting the mRNA of 
PRDM16, a master gene for brown fat determination, 
miR-133 modulates the choice between the myogenic 
and brown adipose lineages during SC differentiation. 
In SCs, HDAC4 expression correlates with that 
of miR-133, and HDAC4 inhibition induces SCs to 
partially differentiate into adipocytes[70]; however, the 
link between HDAC4 and miR-133 has not been yet 
characterized. Moreover, by modulating the insulin-like 
growth factor (IGF)-1 pathway via the downregulation 
of the IGF-1 receptor, miR-133a promotes SC diffe-
rentiation[94] and sarcomeric actin organization[95]. In 
differentiating myoblasts, the repression of tumor 
growth factor-beta signaling, which is known to nega-
tively affect SC differentiation, is ensured by the 
combined activity of miR-26a, which represses Smad1 
and Smad4 expression[96], miR-206 and miR-29, which 
are capable of inhibiting Smad3 expression[97]. Together 
with myomiRs whose expression is upregulated during 
SC differentiation, the expression of other microRNAs 
needs to be down-regulated in order to achieve SC 
terminal differentiation. One such example is miR-23a, 
which directly regulates the expression of myosin heavy 
chain genes[98].
CONCLUSION
The maintenance of skeletal muscle homeostasis is a key 
survival factor, considering that skeletal muscle accounts 
for approximately 40% of body mass. Skeletal muscle 
needs to efficiently respond to internal and external 
stimuli - such as changes in levels of blood sugar, 
circulating hormones, or growth factors or mechanical 
insults - or to pathological conditions to maintain 
homeostasis, particularly in muscle. Unequivocally, SCs 
play central roles in adult regenerative myogenesis and 
in the preservation of muscle mass. Different epigenetic 
marks contribute to the coordination of the precise time-
dependent expression of different subsets of myogenic 
genes in SCs (Table 1 and Figure 1). For instance, the 
PcG catalytic subunit Ezh2 is specifically distributed 
on the regulatory regions of late but not early muscle 
genes[60], whereas the methyltransferases PRMT5 and 
CARM1 are detected on promoters of early and late 
muscle genes, respectively[99].
Despite the observation that most muscular diseases 
do not have an epigenetic cause per se, the importance 
of epigenetic pathways in modulating muscle-specific
gene expression renders them as excellent candidate 
targets for disease interventions. For instance, an 
elegant study demonstrated that epigenetic commitment 
mediated by SMARCD3, a member of the SWI/SNF 
family of proteins, and MyoD is required for the efficient 
generation of skeletal muscle cells from human embryonic 
stem cells[100]. Several drugs that target epigenetic 
mechanisms are currently undergoing clinical trials for 
many diseases. These drugs include HDAC inhibitors[101] 
and HMT inhibitors alone[102] or in combination[103]. In 
amyotrophic lateral sclerosis, HDAC inhibitors have 
been proposed as potential drugs to ameliorate patient 
symptoms[104,105]. In the case of muscular dystrophy, 
HDAC inhibitors have been extensively studied using 
the mdx mouse model[106]; currently, these drugs are 
under review in a clinical trial for muscular dystrophy[107]. 
Their effects are believed to be primarily due to the 
inhibition of class Ⅰ HDACs[108]. However, the prolonged 
treatment of patients with drugs that inhibit these 
ubiquitously required chromatin-modifying enzymes is a 
potential concern. An alternative approach ideally relies 
on the identification of small molecules that interfere 
with the epigenetic enzymes to specific loci within the 
genome. This approach may provide similar benefits 
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without exerting side effects caused by the modification 
of gene expression in other cell types. In the last few 
years, numerous studies involving RNA-seq or ChIP-seq 
have contributed to provide a picture of the epigenetic 
characteristics of muscle-specific gene promoters during 
the different stages of myogenesis. However, most of 
these studies were performed using muscle cell lines 
and remain to be validated using in vivo models, for 
instance by analyzing mice in which individual epigenetic 
regulators are inactivated in a muscle-specific manner. 
The elucidation of the epigenetic mechanisms regulating 
SC function might reveal new targets for pharmacological 
manipulation to improve muscle regeneration and 
to promote muscle homeostasis under pathological 
Table 1  Summary of the main epigenetic events regulating the satellite cells status during myogenesis
SC status Epigenetic regulation Ref.
Quiescent ↓ H3K27me31 and ↑ H3K4me32 [59,60]
Bivalent domains (H3K27me3 + H3K4me3) [59]
↑ miR-489 ┤DEK3 [57]
↑ miR-31 ┤Myf54 [58]
Activated ↑ H3K4me3 on cell cycle genes [19]
↑ H3K27me3 on the Pax75 gene [65]
↑ P38 γ-MAPK6 → p-MyoD7 + KMT1A8 ┤myogenin [66]
MyoD + HDAC19 ┤p2110 and muscle genes [67,68]
HDAC4/511 ┤MEF212 [69]
HDAC4 → Pax7, Lix113 [70]
↑ miR-27a/b ┤myostatin and Pax313 [71,72]
↑ miR-133a ┤serum response factor [73]
↑ miR-206 ┤TIMP314 and Pax3 [75,76]
Differentiating ↑ H3K27me3 on cell cycle and alternative fate genes [59,64,65,76-78]
↑ H3K43me on Myf5 [19]
↓ HDAC1 → MyoD-dependent genes [68]
HDAC4/5 in the cytoplasm → MEF2 [69]
↑ P38 α/β-MAPK15 → SWI-SNF16 → myogenin and creatine kinase genes [82,83]
↑ miR-214, miR-26a, and miR-29 ┤Ezh217 and YY118 [84-86]
↑ miR-128a, miR-26a, miR-1, miR-206, miR-133a, and miR-133b ┤cell cycle [87,88,90,91]
↑ miR-206 ┤notch319, igfbp520, Meox221, RARB22, Fzd723,MAP4K324,CLCN325, and NFAT526 [59,89]
↑ miR-133a ┤PRDM1627 and the IGF-128 receptor [78,80]
↑ miR-26a ┤Smad129 and Smad430 [96]
↑ miR-206 and miR-29 ┤Smad331 [97]
↓ miR-23a ┤myosin heavy chain [98]
1Trimethylated histone H3 lysine 27 (H3K27me3); 2Trimethylated histone H3 lysine 4 (H3K4me3); 3DEK oncogene; 4Myogenic 
factor 5; 5Paired box 7; 6p38 gamma mitogen-activated protein kinase (P38 MAPK); 7Phospho-myogenic differentiation; 8Also 
referred to as suppressor of variegation 3-9 homolog 1 (Suv39h1); 9Histone deacetylase 1; 10Cyclin-dependent kinase inhibitor 
1A; 11Histone deacetylase 4/5; 12Limb expression 1 homolog (chicken); 13Paired box 3; 14TIMP metallopeptidase inhibitor 3; 15p38 
alpha/gamma mitogen-activated protein kinase; 16SWI/SNF complex; 17Enhancer of zeste homolog 2; 18YY1 transcription factor; 
19Neurogenic locus notch homolog protein 3 gene; 20Insulin-like growth factor binding protein 5; 21Mesenchyme homeobox 2 
(Meox2); 22Retinoic acid receptor, beta (RARB); 23Frizzled class receptor 7 (Fzd7); 24Mitogen-activated protein kinase kinase kinase 
kinase 3 (MAP4K3); 25Chloride channel, voltage-sensitive 3 (CLCN3); 26Nuclear factor of activated T-cells 5, tonicity-responsive 
(NFAT5); 27PR domain containing 16 (PRDM16); 28Insulin-like growth factor 1 (IGF-1); 29SMAD family member 1; 30SMAD family 
member 4; 31SMAD family member 3. HDAC: Histone deacetylase. 
Quiescent
SC
miR-31 miR-489
PRC2
(MyoD SRF
Myogenin)
Activated
SC
HDAC 1 miR-23a KMT1A
PRC2
(Pax7)
Class Ⅱ
HDACs Differentiating
SC
TrxG
miR-27a/b
miR-133a
miR-682
KDM4A
HP1
PcG SWI/SNF miR-133
miR-206
miR-1
miR-128
miR-214
miR-29
miR-26a
Figure 1  Schematic diagram of the epigenetic control of satellite cells during their activation and differentiation. SC: Satellite cells; PRC2: Polycomb 
repressive complex 2; TrxG: Trithorax group; PcG: Polycomb group; HDAC: Histone deacetylase.
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